MSWA
FDMT icon

Marshall & Sterling Wealth Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Marshall & Sterling Wealth Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$931 Hold
100
– – ﹤0.01% 310
2025
Q4 		$750 Hold
100
– – ﹤0.01% 315
2025
Q3 		$869 Buy
+100
New +$598 ﹤0.01% 603

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Marshall & Sterling Wealth Advisors's FDMT Position: Q1 2026 in Review

Marshall & Sterling Wealth Advisors held its 4D Molecular Therapeutics (FDMT) position steady in Q1 2026 at 100 shares worth $931. The position accounts for ﹤0.01% of the portfolio, ranked #310.

Marshall & Sterling Wealth Advisors first reported a position in FDMT in Q3 2025 and has held it in 3 quarters since. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Marshall & Sterling Wealth Advisors held 100 shares of 4D Molecular Therapeutics worth $931 as of Q1 2026.
  • Marshall & Sterling Wealth Advisors left its 4D Molecular Therapeutics share count unchanged in Q1 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Marshall & Sterling Wealth Advisors's portfolio in Q1 2026, its #310 holding.
  • Marshall & Sterling Wealth Advisors first reported a position in 4D Molecular Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Marshall & Sterling Wealth Advisors's 13F filing for Q1 2026, filed 7 May 2026.